



# **Transparency notification FMR LLC**

# Brussels (Belgium), 25 May 2022 – 20:00 (CEST) – Regulated information

# 1. Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it received a transparency notification from FMR LLC. (having its registered office at The Corporation Trust Center, 1209 Orange Street, Wilmington, New Castle County, Delaware, 19801, U.S.A.) on 24 May 2022.

FMR LLC., notified that, following an acquisition of UCB shares with voting rights by its affiliates, its shareholding in UCB SA increased and crossed the 5% threshold on 18 May 2022.

On 18 May 2022, FMR LLC. (taking into account the holding of its affiliates) owned 9 763 725 UCB shares with voting rights, representing 5.02% of the total number of shares issued by the company (194 505 658), versus 4.99% (9 714 254 UCB shares) in the previous notification dated 23 May 2022.

# 2. Content of the notification

- **Reason for the notification**: Acquisition or disposal of voting securities or voting rights.
- Notification by: A parent undertaking or a controlling person.
- Persons subject to the notification requirement:

	Name	Address (for legal entities)
F	MRIIC	The Corporation Trust Center, 1209 Orange Street, Wilmington, New Castle County, Delaware, 19801.

- Date on which the threshold is crossed: 18 May 2022.
- Threshold crossed (in %): 5%.
- **Denominator**: 194 505 658.







### • Notified details:

A) Voting rights	Previous notification	After the transaction					
	# of voting rights	# of voting rights		% of voting rights			
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities		
FMR LLC	0	0		0,00%			
FIAM LLC	863.989	868.189		0,45%			
Fidelity Institutional Asset Management Trust Company	448.349	455.749		0,23%			
Fidelity Management & Research Company LLC	7.433.517	7.472.126		3,84%			
Fidelity Management Trust Company	616.056	616.056		0,32%			
FMR Investment Management (UK) Limited	180.200	180.200		0,09%			
Strategic Advisers LLC	172.143	171.405		0,09%			
Subtotal	9.714.254	9.763.725		5,02%			
TOTAL		9.763.725	0	5,02%	0,00%		

B) Equivalent financial instruments	After the transaction							
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement		
TOTAL					0,00%			
TOTAL (A & B)			# of voting rights	% of voting rights				
CALCULATE				9.763.725	5,02%			

# • Chain of controlled undertakings through which the holding is effectively held:

Fidelity Institutional Asset Management Trust Company and FIAM LLC are controlled by FIAM Holdings LLC, FIAM Holdings LLC is controlled by FMR LLC Fidelity Management Trust Company is controlled by FMR LLC Fidelity Management & Research Company LLC is controlled by FMR LLC FMR Investment Management (UK) Limited is controlled by Fidelity Management & Research Company LLC Strategic Advisers LLC is controlled by Fidelity Advisory Holdings LLC Fidelity Advisory Holdings LLC is controlled by FMR LLC FMR LLC is not a controlled entity.







• Additional information: The holdings attributed to the entities mentioned in heading 10 arise from holdings of various undertakings for collective investment that are managed by FIAM LLC, Fidelity Institutional Asset Management Trust Company, Fidelity Management & Research Company LLC, Fidelity Management Trust Company, FMR Investment Management (UK) Limited and Strategic Advisers LLC each of which are entities that are subsidiaries of and controlled by FMR LLC. The entities mentioned in heading 10 are the discretionary investment managers and exercise the voting rights at their discretion in the absence of specific instructions.

### 3. Further information

This press release and the detailed transparency notification are available on UCB SA/NV's website via the following <u>link</u>.

An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV's website via the following <u>link</u>.

For further information, contact UCB:

Investor Relations Antje Witte T +32 2 559 94 14 antje.witte@ucb.com

Corporate Communications Laurent Schots T+32 2 559 92 64 laurent.schots@ucb.com

#### About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 600 people in nearly 40 countries, the company generated revenue of  $\in$  5.8 billion in 2021. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB\_news

